Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.

Current Alzheimer Research
Kelly CeyzériatBenjamin B Tournier

Abstract

Alzheimer's Disease (AD) is the most common neurodegenerative disease and cause of dementia. Characterized by amyloid plaques and neurofibrillary tangles of hyperphosphorylated Tau, AD pathology has been intensively studied during the last century. After a long series of failed trials of drugs targeting amyloid or Tau deposits, currently, hope lies in the positive results of one Phase III trial, highly debated, and on other ongoing trials. In parallel, some approaches target neuroinflammation, another central feature of AD. Therapeutic strategies are initially evaluated on animal models, in which the various drugs have shown effects on the target (decreasing amyloid, Tau and neuroinflammation) and sometimes on cognitive impairment. However, it is important to keep in mind that rodent models have a less complex brain than humans and that the pathology is generally not fully represented. Although they are indispensable tools in the drug discovery process, results obtained from animal models must be viewed with caution. In this review, we focus on the current status of disease-modifying therapies targeting amyloid, Tau and neuroinflammation with particular attention on the discrepancy between positive preclinical results on animal...Continue Reading

References

Apr 10, 1992·Science·J A Hardy, G A Higgins
Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Nov 5, 2002·The American Journal of Pathology·Michael DeTureShu-Hui Yen
Apr 4, 2003·The New England Journal of Medicine·Barry ReisbergUNKNOWN Memantine Study Group
Aug 5, 2003·The Journal of Clinical Investigation·Jason L EriksenTodd E Golde
Jul 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·René EtcheberrigarayDaniel L Alkon
May 11, 2005·Neurology·S GilmanUNKNOWN AN1792(QS-21)-201 Study Team
Aug 1, 2006·Lancet·Kaj BlennowHenrik Zetterberg
Oct 14, 2006·Journal of Neural Transmission·R Schliebs, T Arendt
Nov 27, 2007·Acta Neuropathologica·Charles DuyckaertsBenoît Delatour
Mar 29, 2008·Acta Neuropathologica·Dietmar Rudolf ThalEstifanos Ghebremedhin
May 5, 2009·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Yao ZhangJian-Zhi Wang
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Robert J van Marum
Nov 17, 2009·Frontiers in Human Neuroscience·Suzana Herculano-Houzel
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·M Paul Murphy, Harry LeVine
Jan 4, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Stephen F CarterAgneta Nordberg
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Darin JaturapatpornNaji Tabet
Sep 1, 2012·Journal of Alzheimer's Disease : JAD·Teodoro del SerTeresa León
Nov 16, 2012·The New England Journal of Medicine·Thorlakur JonssonKari Stefansson
Nov 16, 2012·The New England Journal of Medicine·Rita GuerreiroUNKNOWN Alzheimer Genetic Analysis Group
Apr 12, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Robert M CohenTerrence Town
Jul 19, 2013·Reviews on Recent Clinical Trials·Michael S Rafii
Aug 21, 2013·Journal of Alzheimer's Disease : JAD·Félix HernándezJesús Avila
Jan 24, 2014·The New England Journal of Medicine·Stephen SallowayUNKNOWN Bapineuzumab 301 and 302 Clinical Trial Investigators

❮ Previous
Next ❯

Citations

Aug 26, 2020·Cells·Benjamin B TournierPhilippe Millet
Jan 20, 2021·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Lingxiao ZhangDaishun Ling
Jan 19, 2021·Journal of Alzheimer's Disease : JAD·Mithilesh PrakashUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Dec 18, 2020·Frontiers in Aging Neuroscience·Season K Wyatt-Johnson, Randy R Brutkiewicz
Feb 9, 2021·Frontiers in Neuroscience·Sabrina ContinoPascal Kienlen-Campard
May 13, 2021·Neuroscience and Biobehavioral Reviews·Nathan S PentkowskiBenjamin J Clark
Jun 20, 2021·Advanced Drug Delivery Reviews·Lingxiao ZhangFangyuan Li
Oct 2, 2021·Scientific Reports·Yesica GloriaBenjamin B Tournier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.